Sativex,a cannabinoid developed together by GW Pharmaceuticals and Otsuka, receives FDA's Fast Track status for advanced cancer pain.
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.
FDA's Fast Track program
facilitates the development of drugs intended to treat serious or lifeâ€‘threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval.
Read the press release here: http://bit.ly/1m6dlQL